[HTML][HTML] An overview of PROTACs: a promising drug discovery paradigm

Z Liu, M Hu, Y Yang, C Du, H Zhou, C Liu, Y Chen… - Molecular …, 2022 - Springer
Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

XJ Liu, HC Zhao, SJ Hou, HJ Zhang, L Cheng… - Bioorganic …, 2023 - Elsevier
Vascular epidermal growth factor receptor-2 (VEGFR-2), as an important tyrosine
transmembrane protein, plays an important role in regulating endothelial cell proliferation …

A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy

WX Zhang, J Huang, XY Tian, YH Liu, MQ Jia… - European journal of …, 2023 - Elsevier
Histone deacetylases, as a new class of anticancer targets, could maintain homeostasis by
catalyzing histone deacetylation and play important roles in regulating the expression of …

[HTML][HTML] Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

X Wu, J Wang, Q Liang, R Tong, J Huang… - Biomedicine & …, 2022 - Elsevier
Focal adhesion kinase (FAK, also known as PTK2) is a tyrosine kinase that regulates
integrin and growth factor signaling pathways and is involved in the migration, proliferation …

Focal adhesion kinase (FAK): its structure, characteristics, and signaling in skeletal system

Y Huang, J Liao, R Vlashi, G Chen - Cellular Signalling, 2023 - Elsevier
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and distributes important
regulatory functions in skeletal system. Mesenchymal stem cell (MSC) possesses significant …

The dawn of precision medicine in diffuse-type gastric cancer

A Ooki, K Yamaguchi - Therapeutic Advances in Medical …, 2022 - journals.sagepub.com
Gastric cancer (GC) is one of the most common malignancies worldwide. The histology-and
morphology-based Lauren classification of GC has been widely used for over 50 years in …

[HTML][HTML] Antitumor activity of s-triazine derivatives: a systematic review

Q Dai, Q Sun, X Ouyang, J Liu, L Jin, A Liu, B He, T Fan… - Molecules, 2023 - mdpi.com
1, 3, 5-triazine derivatives, also called s-triazines, are a series of containing-nitrogen
heterocyclic compounds that play an important role in anticancer drug design and …

Annual review of PROTAC degraders as anticancer agents in 2022

X Wang, ZL Qin, N Li, MQ Jia, QG Liu, YR Bai… - European Journal of …, 2024 - Elsevier
Following nearly two decades of development, significant advancements have been
achieved in PROTAC technology. As of the end of 2022, more than 20 drugs have entered …

Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy

XJ Liu, XJ Pang, XY Yuan, GX Yu, YR Li… - Bioorganic & medicinal …, 2021 - Elsevier
Bruton tyrosine kinase (BTK) is a key kinase in the B cell antigen receptor signal
transduction pathway, which is involved in the regulation of the proliferation, differentiation …

Dual roles of FAK in tumor angiogenesis: A review focused on pericyte FAK

J Zhang, W Li, W Wang, Q Chen, Z Xu, M Deng… - European Journal of …, 2023 - Elsevier
Focal adhesion kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), is a
ubiquitously expressed non-receptor tyrosine kinase, that plays a pivotal role in integrin …